Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer.
Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer.
复制标题
微波消融加卡瑞利珠单抗单药或联合治疗非小细胞肺癌。
DOI：
10.3389/fonc.2022.938827
复制
发表时间：
2022
影响因子：
4.7
通讯作者：
Ye, Xin
中科院分区：
文献类型：
--
作者：
Huang, Yahan;Wang, Jiao;Hu, Yanting;Cao, Pikun;Wang, Gang;Cai, Hongchao;Wang, Meixiang;Yang, Xia;Wei, Zhigang;Ye, Xin
关键词：
Immunotherapy has become widely applied in non-small cell lung cancer (NSCLC) patients. However, the relatively low response rate of immunotherapy monotherapy restricts its application. Combination therapy improves the response rate and prolongs patient survival; however, adverse events (AEs) associated with immunotherapies increase with combination therapy. Therefore, exploring combination regimens with equal efficacy and fewer AEs is urgently required. The aim of this study was to evaluate the efficacy and safety of microwave ablation (MWA) plus camrelizumab monotherapy or combination therapy in NSCLC. Patients with pathologically confirmed, epidermal growth factor receptor/anaplastic lymphoma kinase-wild-type NSCLC were retrospectively enrolled in this study. Patients underwent MWA to the pulmonary lesions first, followed by camrelizumab monotherapy or combination therapy 5–7 days later. Camrelizumab was administered with the dose of 200 mg every 2 to 3 weeks. Treatment was continued until disease progression or intolerable toxicities. The technical success and technique efficacy of ablation, objective response rate (ORR), progression-free survival (PFS), overall survival (OS), complications of ablation, and AEs were recorded. From January 1, 2019 to December 31, 2021, a total of 77 patients underwent MWA and camrelizumab monotherapy or combination therapy. Technical success was achieved in all patients (100%), and the technique efficacy was 97.4%. The ORR was 29.9%. The PFS and OS were 11.8 months (95% confidence interval, 9.5–14.1) and not reached, respectively. Smoking history and response to camrelizumab were correlated with PFS, and response to camrelizumab was correlated with OS in both the univariate and multivariate analyses. No periprocedural deaths due to ablation were observed. Complications were observed in 33 patients (42.9%). Major complications included pneumothorax (18.2%), pleural effusion (11.7%), pneumonia (5.2%), bronchopleural fistula (2.6%), and hemoptysis (1.3%). Grade 3 or higher AEs of camrelizumab, including reactive capillary endothelial proliferation, fatigue, pneumonia, edema, and fever, were observed in 10.4%, 6.5%, 5.2%, 2.6%, and 2.6% of patients, respectively. MWA combined with camrelizumab monotherapy or combination therapy is effective and safe for the treatment of NSCLC.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
8.8
作者：
Ni, Yang;Peng, Jinchao;Ye, Xin
通讯作者：
Ye, Xin
影响因子：
1.3
作者：
Wei, Zhigang;Yang, Xia;Wen, Qiang
通讯作者：
Wen, Qiang
抗 PD-1 加安罗替尼治疗既往全身治疗失败后晚期非小细胞肺癌患者的疗效和安全性——一项回顾性研究
影响因子：
4.7
作者：
Wang P;Fang X;Yin T;Tian H;Yu J;Teng F
通讯作者：
Teng F
影响因子：
2.9
作者：
Han, Xiaoying;Yang, Xia;Ye, Xin
通讯作者：
Ye, Xin